29 results
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
3 Nov 23
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
8:10am
anticipates regulatory filings in its fiscal year 2024
Ovid recently hosted an R&D Day during which the Company announced indication and formulation … at its R&D Day animal studies that validate OV350's anti-psychotic properties. Non-epilepsy indications may represent future development collaboration
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
2 Oct 23
Dawn of the neurotherapeutics era Dr. Jeremy Levin CEO & Chairman
12:15pm
OVID R&D DAY OCTOBER 2, 2023
Dawn of the neurotherapeutics era Dr. Jeremy Levin CEO & Chairman
Forward looking statement This presentation contains
8-K
EX-99.1
cz033ohq
4 Aug 23
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
9:10am
8-K
EX-99.1
51k60b9 qnsno9rk19
5 May 23
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
8:16am
8-K
EX-99.1
rgwx8bi3ar0 rdb
15 Mar 22
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results
8:29am
8-K
EX-10.1
pid w58wyyc
3 Jan 22
Entry into a Material Definitive Agreement
7:00am
8-K
EX-99.1
da682s
3 Jan 22
Entry into a Material Definitive Agreement
7:00am
8-K
EX-99.1
m17uxva826y
18 Aug 21
Regulation FD Disclosure
8:05am
8-K
EX-99.1
uq2oj7ruo395
23 Jun 21
Regulation FD Disclosure
8:05am
8-K
EX-99.1
ljji2xdo8zmiskaed0k
18 May 21
Regulation FD Disclosure
3:11pm
8-K
EX-99.1
y5gybtkwpqtzb
19 Apr 21
Regulation FD Disclosure
4:22pm
8-K
EX-99.1
ekgsaweul2prcxaxx
9 Apr 21
Regulation FD Disclosure
10:01am
8-K
EX-99.1
y32jbg0pdk
3 Mar 21
Regulation FD Disclosure
10:05am
8-K
EX-99.1
cdjmndav703
25 Aug 20
Other Events
7:00am
8-K
EX-99.1
ue3imd454u vqy1u
17 Jun 20
Regulation FD Disclosure
1:11pm